Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods
Berislav Bošnjak, Saskia C. Stein, Stefanie Willenzon, et al.
Cellular and Molecular Immunology (2020) Vol. 18, Iss. 4, pp. 936-944
Open Access | Times Cited: 122

Showing 1-25 of 122 citing articles:

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
Joana Barros‐Martins, Swantje I. Hammerschmidt, Anne Cossmann, et al.
Nature Medicine (2021) Vol. 27, Iss. 9, pp. 1525-1529
Open Access | Times Cited: 412
Relationship of SARS-CoV-2–specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection
Catherine Riou, Elsa Du Bruyn, Cari Stek, et al.
Journal of Clinical Investigation (2021) Vol. 131, Iss. 12
Open Access | Times Cited: 145
Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant
Maren Schubert, Federico Bertoglio, Stephan Steinke, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 77
Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma
Christine von Rhein, Tatjana Scholz, Lisa Henß, et al.
Journal of Virological Methods (2020) Vol. 288, pp. 114031-114031
Open Access | Times Cited: 90
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination
Alina Tscherne, Jan Hendrik Schwarz, Cornelius Rohde, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 28
Open Access | Times Cited: 85
Evaluation of High-Throughput SARS-CoV-2 Serological Assays in a Longitudinal Cohort of Patients with Mild COVID-19: Clinical Sensitivity, Specificity, and Association with Virus Neutralization Test
Antonin Bal, Bruno Pozzetto, Mary‐Anne Trabaud, et al.
Clinical Chemistry (2021) Vol. 67, Iss. 5, pp. 742-752
Open Access | Times Cited: 82
Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection
Eric H. Y. Lau, David S.C. Hui, Owen TY Tsang, et al.
EClinicalMedicine (2021) Vol. 41, pp. 101174-101174
Open Access | Times Cited: 79
One year of SARS-CoV-2 evolution
Aiping Wu, Lulan Wang, Hangyu Zhou, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 4, pp. 503-507
Open Access | Times Cited: 77
COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions
Opeyemi S. Adeniji, Leila B. Giron, Mansi Purwar, et al.
mBio (2021) Vol. 12, Iss. 2
Open Access | Times Cited: 75
Natural killer cell‐mediated ADCC in SARS‐CoV‐2‐infected individuals and vaccine recipients
Kerri Hagemann, Kristoffer Riecken, Johannes M. Jung, et al.
European Journal of Immunology (2022) Vol. 52, Iss. 8, pp. 1297-1307
Open Access | Times Cited: 60
Evaluation of a commercial ELISA as alternative to plaque reduction neutralization test to detect neutralizing antibodies against SARS-CoV-2
Natalie Hofmann, Marica Grossegesse, Markus Neumann, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 39
Diagnostics and analysis of SARS-CoV-2: current status, recent advances, challenges and perspectives
Tao Dong, Mingyang Wang, Junchong Liu, et al.
Chemical Science (2023) Vol. 14, Iss. 23, pp. 6149-6206
Open Access | Times Cited: 35
Advances in Neutralization Assays for SARS‐CoV‐2
Yuying Lu, Wang Jin, Qianlin Li, et al.
Scandinavian Journal of Immunology (2021) Vol. 94, Iss. 3
Open Access | Times Cited: 51
Surveilling and Tracking COVID-19 Patients Using a Portable Quantum Dot Smartphone Device
Yuwei Zhang, Ayden Malekjahani, Buddhisha Udugama, et al.
Nano Letters (2021) Vol. 21, Iss. 12, pp. 5209-5216
Closed Access | Times Cited: 47
Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents
Berislav Bošnjak, Ivan Odak, Joana Barros‐Martins, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 47
Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort
Alexandra Rockstroh, Johannes Wolf, Jasmin Fertey, et al.
Emerging Microbes & Infections (2021) Vol. 10, Iss. 1, pp. 774-781
Open Access | Times Cited: 45
Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance
Prerna Arora, Amy Kempf, Inga Nehlmeier, et al.
Cellular and Molecular Immunology (2021) Vol. 18, Iss. 11, pp. 2557-2559
Open Access | Times Cited: 44
A scalable and highly immunogenic virus‐like particle‐based vaccine against SARS‐CoV‐2
Mona O. Mohsen, Ina Baļķe, Simon Zinkhan, et al.
Allergy (2021) Vol. 77, Iss. 1, pp. 243-257
Open Access | Times Cited: 43
Comparison of SARS-CoV-2 Antibody Responses and Seroconversion in COVID-19 Patients Using Twelve Commercial Immunoassays
Sojeong Yun, Ji Hyeong Ryu, Joo Hee Jang, et al.
Annals of Laboratory Medicine (2021) Vol. 41, Iss. 6, pp. 577-587
Open Access | Times Cited: 40
BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
Georg M. N. Behrens, Joana Barros‐Martins, Anne Cossmann, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 36
Mutational Pattern, Impacts and Potential Preventive Strategies of Omicron SARS-CoV-2 Variant Infection
Endeshaw Chekol Abebe, Markeshaw Tiruneh G Medhin, Awgichew Behaile T Mariam, et al.
Infection and Drug Resistance (2022) Vol. Volume 15, pp. 1871-1887
Open Access | Times Cited: 30
Neutralizing Antibodies and Cellular Immune Responses Against SARS-CoV-2 Sustained One and a Half Years After Natural Infection
Lina Yan, Panpan Liu, Xu-gui Li, et al.
Frontiers in Microbiology (2022) Vol. 12
Open Access | Times Cited: 29
Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals
Brian Grunau, Martin A. Prusinkiewicz, Michael Asamoah-Boaheng, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 5
Open Access | Times Cited: 29
Importance, Applications and Features of Assays Measuring SARS-CoV-2 Neutralizing Antibodies
Pia Gattinger, Anna Ohradanova‐Repic, Rudolf Valenta
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5352-5352
Open Access | Times Cited: 19
More antibodies are not always better: Fc effector functions play a critical role in SARS-CoV-2 infection and protection
Alberto Rubio‐Casillas, Elrashdy M. Redwan, Vladimir N. Uversky
Progress in molecular biology and translational science (2025)
Closed Access
Page 1 - Next Page

Scroll to top